Whittier Trust Co. Boosts Stake in RadNet, Inc. $RDNT

Posted by Geri Gentry on Jul 6th, 2026

Whittier Trust Co. boosted its position in shares of RadNet, Inc. (NASDAQ:RDNT – Free Report) by 10.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 241,509 shares of the medical research company’s stock after buying an additional 22,216 shares during the period. Whittier Trust Co. owned approximately 0.31% of RadNet worth $13,297,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in RDNT. Mairs & Power Inc. increased its stake in RadNet by 68.9% during the third quarter. Mairs & Power Inc. now owns 97,483 shares of the medical research company’s stock worth $7,429,000 after acquiring an additional 39,752 shares during the last quarter. Neuberger Berman Group LLC increased its position in shares of RadNet by 59.4% during the 3rd quarter. Neuberger Berman Group LLC now owns 456,855 shares of the medical research company’s stock valued at $34,817,000 after purchasing an additional 170,261 shares during the last quarter. Nations Financial Group Inc. IA ADV bought a new position in shares of RadNet during the 4th quarter valued at approximately $1,118,000. Campbell Newman Asset Management Inc. purchased a new stake in RadNet during the 4th quarter valued at $1,773,000. Finally, Fred Alger Management LLC raised its holdings in RadNet by 50.7% during the 3rd quarter. Fred Alger Management LLC now owns 490,267 shares of the medical research company’s stock valued at $37,363,000 after buying an additional 164,842 shares during the period. Hedge funds and other institutional investors own 77.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on RDNT shares. Barclays dropped their price objective on shares of RadNet from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Wednesday, May 20th. Weiss Ratings lowered shares of RadNet from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, May 12th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $87.43.

View Our Latest Research Report on RDNT

Insiders Place Their Bets

In related news, CEO Cornelis Wesdorp sold 4,750 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total value of $276,022.50. Following the transaction, the chief executive officer owned 69,075 shares of the company’s stock, valued at $4,013,948.25. This trade represents a 6.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David L. Swartz sold 2,699 shares of RadNet stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $53.89, for a total transaction of $145,449.11. Following the sale, the director owned 177,013 shares of the company’s stock, valued at $9,539,230.57. The trade was a 1.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.60% of the stock is currently owned by insiders.

RadNet Stock Performance

Shares of NASDAQ RDNT opened at $68.75 on Monday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.17 and a current ratio of 1.17. The business’s 50 day moving average price is $56.57 and its 200-day moving average price is $63.28. RadNet, Inc. has a fifty-two week low of $50.76 and a fifty-two week high of $85.84. The company has a market cap of $5.41 billion, a price-to-earnings ratio of -381.92 and a beta of 1.37.

RadNet (NASDAQ:RDNT – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The medical research company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). RadNet had a negative net margin of 0.66% and a positive return on equity of 2.77%. The business had revenue of $575.63 million during the quarter, compared to the consensus estimate of $557.93 million. During the same period last year, the company earned ($0.50) EPS. The business’s revenue was up 22.1% compared to the same quarter last year. On average, sell-side analysts expect that RadNet, Inc. will post 0.54 earnings per share for the current year.

About RadNet

(Free Report)

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.